Artelo Files Patent for ART27.13 Obesity Combo; Stock Surges 194%
ARTL has more than doubled off its 52-week low of $3.45 on elevated volume (53× avg).
Summary
Artelo filed a provisional patent covering ART27.13 for obesity, both alone and combined with GLP-1 drugs like semaglutide. The filing follows expanded DIO-2 data showing 40% weight loss when combined with semaglutide versus 20% for either drug alone, with 80% of lost weight being fat. Management called the bone density increase in the combo group particularly notable given GLP-1 muscle/bone loss concerns. Shares surged 194% to $12.20 on the news. This builds on the Sept 16 obesity data release and the recent 1-for-9 reverse split, with the company still facing going concern doubts and a $75M shelf registration.
At the time of this announcement, ARTL was trading at $7.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $3.45 to $179.19. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.